OLMA SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 10, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 16, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 10, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Olema Pharmaceuticals Announces Board of Directors Resignation and Committee Appointment

Oct 15, 2026

8-K

Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer

Aug 13, 2026

8-K

Olema Oncology Reports Second Quarter 2026 Financial and Operating Results

Aug 10, 2026

8-K

Olema Pharmaceuticals, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 23, 2026

8-K

Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer for OP-3136

May 26, 2026

8-K

Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136

May 21, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Nov 19, 2025

424B5

PENDING FIXED PRICE OFFERING | Bank: TD Cowen

Nov 18, 2025

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Jan 15, 2025

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Jan 15, 2025

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 13,211,381

Feb 12, 2024

424B5

ATM | Offering amount: $150,000,000

Jan 5, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 16, 2026

S-3ASR

SHARE RESALE REGISTRATION | Offering amount: $200,000,000

Dec 11, 2025

S-3MEF

Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)]

Nov 18, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 18, 2025

S-3

Form S-3 - Registration statement under Securities Act of 1933

Jan 6, 2025

S-3

Form S-3 - Registration statement under Securities Act of 1933

Jan 3, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 26, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 26, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13D/A

BIOTECHNOLOGY VALUE FUND L P (Filed by)

Oct 16, 2026

O'Byrne Jason (Reporting)

Sep 2, 2026

O'Byrne Jason (Reporting)

Aug 13, 2026

SCHEDULE 13G/A

FMR LLC (Filed by)

Aug 6, 2026

SCHEDULE 13G/A

BlackRock, Inc. (Filed by)

Jul 29, 2026

Harmon Cyrus (Reporting)

Jul 27, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jan 16, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Jan 16, 2025

CORRESP

Form CORRESP - Correspondence

Jan 13, 2025

CORRESP

Form CORRESP - Correspondence

Jan 13, 2025

LETTER

Form UPLOAD - SEC-generated letter

Jan 8, 2025

LETTER

Form UPLOAD - SEC-generated letter

Jan 8, 2025

Olema Pharmaceuticals, Inc. OLMA · SEC Filings